CRB Completes Facility Construction for GRAM COVID-19 Vaccine Manufacturing

October 1, 2020

The 60,000-ft2 facility was built using CRB’s ONEsolution project delivery method and was designed to expand GRAM’s large-scale fill/finish capacity.

Grand River Aseptic Manufacturing (GRAM) and CRB, a Plymouth Meeting, PA-based integrated project delivery solutions provider, announced on Oct. 1, 2020 that CRB has completed the construction of a large-scale facility for GRAM for the increase of domestic pharmaceutical manufacturing for COVID-19 vaccines and therapeutics.

The 60,000-ft2 facility was built using CRB’s ONEsolution project delivery method and was designed to expand GRAM’s large-scale fill/finish capacity, a CRB press release said. The newest site is one of three GRAM pharmaceutical manufacturing facilities located in Grand Rapids, MI.

“Through close collaboration and enhanced planning with GRAM’s project team, the facility’s operational turn-over, validation, and equipment start-up began earlier than otherwise possible, allowing GRAM to begin qualifications and media fills early this year,” said Jesse Adams, project manager for CRB, in the press release.

“When choosing a design-build partner for our new facility, we needed a team we could rely on to ensure the project would be completed to meet all required regulatory requirements as well as on time and on budget, and we found that with CRB,” said John Wichelt, vice president, Client Pharmaceutical Services at GRAM, in the press release. “Our new facility gives GRAM the capacity, technology, and equipment to support urgent response efforts, starting with US-based manufacturing in the fight against COVID-19.”

GRAM announced on Sept. 25, 2020, that it will support the fill/finish manufacture of Janssen Pharmaceuticals’ SARS-CoV-2 vaccine candidate.

Source: CRB